Evidence map›Paper›PMID 40729807›Full record

ArticleJournal of pharmaceutical and biomedical analysis2025

Formulation insights into competitive binding of N

Seungil Cho, Carl Murphy, Thomas Green, Kelly Drew

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical and biomedical analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Seungil ChoInstitute of Arctic Biology, University of Alaska Fairbanks, AK, United States. Electronic address: sicho@alaska.edu.
Carl MurphyInstitute of Arctic Biology, University of Alaska Fairbanks, AK, United States.
Thomas GreenDepartment of Chemistry and Biochemistry, University of Alaska Fairbanks, AK, United States.
Kelly DrewInstitute of Arctic Biology, University of Alaska Fairbanks, AK, United States; Department of Chemistry and Biochemistry, University of Alaska Fairbanks, AK, United States.

Funding

The Administrative CoreP20GM103395 · NIGMS · UNIVERSITY OF ALASKA FAIRBANKS · PI BRIAN M BARNES · 2012 to 2026
$66.1M
Renovation of LARS for Arctic Ground Squirrel BreedingP20GM130443 · NIGMS · UNIVERSITY OF ALASKA FAIRBANKS · PI KELLY L DREW · 2019 to 2026
$16.4M
NIGMS NIH HHS P20 GM103395NIGMS NIH HHS P20 GM130443
6 · The paper itself

Abstract

This study investigates the molecular interactions and physicochemical properties of N

Indexed as

2-Hydroxypropyl-beta-cyclodextrinAdenosineTheophyllineBinding, CompetitiveChemistry, PharmaceuticalDrug CompoundingElectrophoresis, CapillaryExcipientsMagnetic Resonance SpectroscopySolubility2-Hydroxypropyl-beta-cyclodextrinAdenosineExcipientsTheophylline2-hydroxypropyl-β-cyclodextrin (HPβCD)8-(p-sulfophenyl)theophylline (8-SPT)Binding constantCapillary ElectrophoresisDrug FormulationN(6)-Cyclohexyladenosine (CHA)NMR Spectroscopy

Identifiers

PMID40729807
PMCPMC12356510

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.